Antiviral adhesive sheet

Abstract

To provide antiviral property imparting means capable of reducing operational complexity and shortening operation time in imparting antiviral properties onto a target object for imparting antiviral properties or a base material thereof, without any problem with regard to environmental hygiene or fire protection due to an organic solvent, while allowing easy re-application.SOLUTION: An antiviral pressure sensitive adhesive sheet includes a sucker adhesive layer laminated on one side of an antiviral agent-containing layer. The sucker adhesive layer contains a one-pack type curable acrylic resin, and an application quantity is 13 g / m2 to 70 g / m2.SELECTED DRAWING: Figure 1

Description

Technical Field

[0001] The present disclosure relates to an antiviral adhesive sheet.

Background Art

[0002] Conventionally, from the viewpoint of hygiene, attempts have been made to impart antiviral properties to the surfaces of objects that are touched by hand, such as interior materials of building walls, floors, ceilings, etc., furniture such as desks, fittings such as doors, interior materials of vehicles, OA equipment, and touch panels. Patent Document 1 discloses that a composition containing a copper-based antiviral agent is directly applied to an object to which antiviral properties are to be imparted to impart antiviral properties. Further, Patent Document 2 discloses an antiviral decorative sheet in which a coating film of a composition containing a silver-based or zinc-based antiviral agent is formed on the surface of various decorative sheets used for surface decoration of building interior materials, furniture, fittings, etc. to impart antiviral properties to the surface in advance. Such an antiviral decorative sheet has also been adhered and laminated on an object to which antiviral properties are to be imparted or on its base material via an adhesive layer such as starch paste or two-component curable urethane resin.

Prior Art Documents

Patent Documents

[0003]

Patent Document 1

Patent Document 2

Summary of the Invention

Problems to be Solved by the Invention

[0004] However, direct application of an antiviral agent onto an object to which antiviral properties are to be imparted, such as interior finishes of buildings, or onto its substrate, involves a lot of preparatory work at the construction site, such as masking (preventing paint adhesion) of non-application areas, painting, drying, and cleanup, which takes a lot of time and labor. The appearance and antiviral performance vary depending on the skill of the painting contractor (craftsman). If the solvent in the paint is an organic solvent, there are also complications such as the need for health and hygiene measures and fire prevention measures. Also, if there are defects, failures, or malfunctions in the result of the application work, redoing the application work requires removing the paint, which is very time-consuming, costly, and difficult. Also, in the case of adhesion or lamination of an antiviral decorative sheet onto an object to which antiviral properties are to be imparted or onto its substrate via an adhesive, as disclosed in Patent Document 2, there is an advantage that the antiviral performance is stabilized at a certain level because quality control is carried out at the factory and the decorative sheet is manufactured. However, on the other hand, similar to the case of direct painting, at the construction site, there is a lot of preparatory work such as mixing and adjusting the adhesive, masking, etc., applying the adhesive, waiting for the adhesion time, and cleanup, which takes a lot of time and labor. The appearance and adhesion performance over time vary depending on the skill of the adhesive application contractor (craftsman). If the solvent in the adhesive is an organic solvent, there are complications such as the need for health and hygiene measures and fire prevention measures. Also, if there are defects, failures, or malfunctions in the result of the adhesion and lamination work, redoing the adhesion work requires removing the adhered decorative sheet, which is very time-consuming, costly, and difficult. Furthermore, as a common problem in both direct application of an antiviral agent and adhesion / lamination of an antiviral decorative sheet, due to the complicated work, long working hours, and high difficulty of rework at the construction site, it is difficult for an amateur to carry out the construction, so-called "DIY" construction.

[0005] The present disclosure aims to provide a means for imparting antiviral properties that reduces the complexity of work, shortens the working hours, has no concerns about environmental hygiene and fire prevention due to organic solvents, and is easy to reapply in imparting antiviral properties onto an object to which antiviral properties are to be imparted or onto its substrate.

Means for Solving the Problems

[0006] In order to solve the above problems, the present disclosure provides an antiviral adhesive sheet formed by laminating an adhesive layer on one side surface of an antiviral agent-containing layer.

[0007] In the above antiviral adhesive sheet, the suction cup adhesive layer may be made of a one-component curable acrylic resin.

[0008] In the above antiviral adhesive sheet, the coating amount of the suction cup adhesive layer is 13 g / m 2 or more and 70 g / m 2 or less.

[0009] In the above antiviral adhesive sheet, the suction cup adhesive layer has a plurality of concave shapes on both sides, and the average value of the diameters of the respective openings of the concave shapes that open on one surface is D ave 1, and the average value of the diameters of the respective openings of the concave shapes that open on the other surface of the suction cup adhesive layer is D ave 2, when |D ave 1 - D ave 2| / D ave 2 ≤ 0.5 may satisfy the relationship.

Advantages of the Invention

[0010] According to the present disclosure, in imparting antiviral properties to an object to which antiviral properties are to be imparted or its substrate, it is possible to provide an antiviral property-imparting means that reduces the complexity of the work, shortens the working time, has no concerns about environmental hygiene and fire prevention due to organic solvents, and is also easy to rework.

Brief Description of the Drawings

[0011]

Figure 1

Figure 2

Figure 3

Mode for Carrying Out the Invention

[0012] 〔Antiviral Adhesive Sheet〕 The antiviral adhesive sheet 100 of the present embodiment has a layer containing an antiviral agent and a suction cup adhesive layer 50. Hereinafter, the "layer containing an antiviral agent" may be referred to as the "antiviral agent-containing layer". Further, when the antiviral agent-containing layer is a single layer (single layer) of the antiviral agent-containing layer, there is also a case where it is composed of a laminate in which other layers that do not contain an antiviral agent such as a base material, an adhesive layer, and a decorative layer are laminated (forms represented by FIGS. 2 and 3). Among the antiviral agent-containing layers having such a laminate structure, the portion of the layer containing an antiviral agent is hereinafter also particularly referred to as the "single-layer antiviral agent-containing layer" or the "single-layer portion of the antiviral agent-containing layer". When the antiviral adhesive sheet 100 of the present embodiment exhibits antibacterial and antifungal properties simultaneously with the expression of antiviral properties, it can also be used as an antibacterial adhesive sheet and an antifungal adhesive sheet.

[0013] Generally, even for articles having the same material and layer structure, the correlation relationships with the "antiviral property", "antibacterial property", and "antifungal property" exhibited may be effective or ineffective depending on the types of viruses, bacteria, and fungi targeted; environmental conditions; the levels of antiviral, antibacterial, and antifungal properties required; etc. For this reason, the antiviral adhesive sheet of the present embodiment may be applicable not only to antiviral applications but also to antibacterial applications depending on the type of bacteria, environmental conditions, and the required level of antibacterial property. Since mold is a type of fungus, the antiviral adhesive sheet of the present embodiment may similarly be applicable to antifungal applications depending on the type of mold, environmental conditions, and the required level of antifungal property.

[0014] FIG. 1(a) is a cross-sectional view showing a typical embodiment of the antiviral agent-containing layer 10 provided with the suction cup adhesive layer 50 constituting the antiviral adhesive sheet 100 of the present disclosure. The antiviral adhesive sheet 100 of FIGS. 1(a) to 1(c) is usually used in a direction such that the XY plane faces a person.

[0015] The antiviral agent-containing layer 10 in FIG. 1(a) contains the antiviral agent 12 throughout the in-plane direction and the thickness direction of the antiviral agent-containing layer 10. The antiviral agent-containing layer 10 in FIG. 1(b) contains the antiviral agent 12 in the vicinity of the surface side (the upper side in the figure) of the antiviral agent-containing layer 10 in its in-plane direction (each direction in the XY plane of the figure). The antiviral agent-containing layer 10 in FIG. 1(c) contains the antiviral agent 12 in a partial region in the in-plane direction of the surface side (the upper side in the figure) of the antiviral agent-containing layer 10. As shown in FIGS. 1(a) to 1(c), in the antiviral agent-containing layer 10, the location where the antiviral agent 12 is present is not particularly limited. However, from the viewpoint of enhancing the antiviral property, it is preferable that the antiviral agent 12 is present in at least a partial region near the surface where the antiviral agent-containing layer 10 is exposed.

[0016] In this specification, the surface where the antiviral agent-containing layer is exposed refers to the surface where the in-plane direction of the antiviral agent-containing layer is exposed. The in-plane direction of the antiviral agent-containing layer is the XY direction in FIGS. 1 to 3. Also, in this specification, the vicinity of the surface where the antiviral agent-containing layer is exposed means the region within the range where the antiviral agent is contained in the thickness direction from the surface where the antiviral agent is exposed. That is, when using the radioactive compound (antiviral agent 6) described later as the antiviral agent 12, antiviral properties can be exhibited even in a form where the antiviral agent 12 is absent on the surface of the antiviral agent-containing layer 10 and only exists inside the layer. However, in the case of using other forms of the antiviral agent 12, the portion that surely exhibits antiviral properties in the antiviral agent-containing layer 10 is the portion where the antiviral agent 12 is exposed to the outside from the antiviral agent-containing layer 10. Therefore, at least one or more layers of the minimum units composed of particles, atoms (including ionized ones), or molecules of the antiviral agent 12 should be present on the surface of the antiviral agent-containing layer 10. For example, when the antiviral agent has an atom or a molecule as the minimum unit, a single atomic layer or a single molecular layer is sufficient. When the antiviral agent has a particle formed by a plurality of atoms or molecules aggregated as the minimum unit, only a single particle layer is sufficient. However, in reality, when forming the antiviral agent 12 as a single atomic layer, a single molecular layer, or a single particle layer on the antiviral agent-containing layer 10, in addition to the difficulty in manufacturing technology, the antiviral agent 12 is easily detached and disappeared by external forces such as friction, and the antiviral function is easily lost. In addition, there may be viruses that penetrate into the antiviral agent-containing layer 10 from the gaps between the antiviral agent and the binder resin.

[0017] Furthermore, the antiviral agent 12 may have the property of bleeding from the inside to the surface of the antiviral agent-containing layer 10 over time. In such a case, the atoms, molecules, or particles of the antiviral agent 12 are configured in two or more layers on the surface of the antiviral agent-containing layer 10, or the antiviral agent 12 is distributed and contained from the surface of the antiviral agent-containing layer 10 to the inside of the layer 10, and a part of the antiviral agent 12 is exposed from the surface of the antiviral agent-containing layer 10. The antiviral agent 12 exposed on the surface layer of the layer 10 exhibits antiviral properties, and the antiviral agent that has fallen off or disappeared from the surface of the antiviral agent-containing layer 10 over time is transferred from the antiviral agent layer immediately below the surface layer of the antiviral agent-containing layer 10, or the antiviral agent 12 that has migrated from the inside of the antiviral agent-containing layer 10 is exposed from the surface of the antiviral agent-containing layer 10 or forms a layer on the surface of the antiviral agent-containing layer 10 to complement it, thereby suppressing the decrease in antiviral function over time. Therefore, in reality, in many cases, atoms, molecules, or particles of the antiviral agent 12 are distributed and contained from the surface of the antiviral agent-containing layer 10 to a depth of a predetermined thickness, and a part of the antiviral agent 12 is configured to be exposed or form a layer from the surface of the antiviral agent-containing layer 10. The region where atoms, etc. of the antiviral agent 12 are distributed and contained from the surface of the antiviral agent-containing layer 10 to a depth of a predetermined thickness is referred to as "near the surface where the antiviral agent-containing layer 10 is exposed".

[0018] Therefore, the thickness range of such "near the surface" may be appropriately designed according to the type of the antiviral agent 12 used, the method of forming or manufacturing the antiviral agent-containing layer 10 in the antiviral adhesive sheet 100, the use of the antiviral adhesive sheet, the durability against friction, etc. of the antiviral agent-containing layer 10, etc. As the thickness near the surface of the typical antiviral agent-containing layer 10, for example, a range of 1 μm or more and 5000 μm or less (however, it does not exceed the thickness of the antiviral agent-containing layer 10) is preferable, and in the case of normal use, required durability, and the method of forming or manufacturing the antiviral agent-containing layer, 3 μm or more and 100 μm or less is more preferable.

[0019] The antiviral adhesive sheet 100 in which the antiviral agent-containing layer 10 is a single layer, as shown in FIGS. 1(a) to 1(c), can be manufactured by, for example, the methods such as the following (A1) and (A2). When an organic antiviral agent is used, the method (A2) is preferable in order to make it less susceptible to the influence of heat or the like during molding and to easily maintain the function of the antiviral agent. (A1) A composition containing a binder resin 11 and an antiviral agent 12 is molded by melt extrusion, injection molding, or the like. (A2) After producing a laminate formed by forming an antiviral agent-containing layer 10 on a substrate having releasability, the substrate having releasability is peeled off from the laminate.

[0020] In the antiviral adhesive sheet 100 of FIGS. 2(a) and 2(b), the antiviral agent-containing layer 10' has a laminated form having a single layer of the antiviral agent-containing layer 10 on the substrate 20. The antiviral agent-containing layer 10' in FIG. 2(a) has a single layer of the antiviral agent-containing layer 10 on the entire surface of one side of the substrate 20. The antiviral agent-containing layer 10' in FIG. 2(b) has a single layer of the antiviral agent-containing layer 10 in a partial region on one side (the + side in the Z-axis direction in the figure) of the substrate 20. As shown in FIGS. 2(a) and 2(b), the single layer of the antiviral agent-containing layer 10 constituting the antiviral agent-containing layer 10' may be formed on the entire surface of the substrate 20 or may be formed on a part of the substrate 20.

[0021] The antiviral agent-containing layer 10' having the substrate 20 and a single layer of the antiviral agent-containing layer 10, as shown in FIGS. 2(a) and 2(b), can be manufactured by, for example, the methods such as the following (B1) to (B4). When an organic antiviral agent is used, the method (B1) or (B4) is preferable in order to make it less susceptible to the influence of heat during lamination of the antiviral agent-containing layer 10 and to easily maintain the function of the antiviral agent. (B1) A composition containing a binder resin 11 and an antiviral agent 12 is applied onto the substrate 20 to form the antiviral agent-containing layer 10 as a coating film, or a sheet formed by forming the same composition into a film is laminated (bonded) through an adhesive layer as necessary. (B2)On the base material 20, a composition containing a binder resin 11 and an antiviral agent 12 is melt-extruded to form an antiviral agent-containing layer 10. (B3)The base material 20 and the antiviral agent-containing layer 10 are heated and welded. (B4)A laminate is produced by forming an antiviral agent-containing layer 10 on a base material having releasability. After the surface of the laminate on the antiviral agent-containing layer 10 side and the base material 20 are brought into close contact with each other, the base material having releasability is peeled off.

[0022] In the antiviral adhesive sheet 100 having the base material 20 and the antiviral agent-containing layer 10 as shown in FIGS. 2(a) and (b), the antiviral agent-containing layer 10' may have other layers such as an adhesive layer 30 and a second base material 40 between the base material 20 and the single-layer antiviral agent-containing layer 10. The antiviral agent-containing layer 10'' in FIG. 3(a) has an adhesive layer 30 between the base material 20 and the single-layer antiviral agent-containing layer 10. Also, the antiviral agent-containing layer 10'' in FIG. 3(b) has a second base material 40 between the base material 20 and the single-layer antiviral agent-containing layer 10. Further, the antiviral agent-containing layer 10'' in FIG. 3(c) has an adhesive layer 30 and a second base material 40 between the base material 20 and the single-layer antiviral agent-containing layer 10.

[0023] The antiviral agent-containing layer 10'' in the antiviral adhesive sheet 100 as shown in FIGS. 3(a) to 3(c) can be produced by, for example, the following methods (C1) to (C5). When an organic antiviral agent is used, in order to easily maintain the function of the antiviral agent, the methods (C1), (C2) or (C5) are preferable. (C1)The single-layer antiviral agent-containing layer 10 and the base material 20 are bonded together via an adhesive layer 30. (C2)The surface of the laminate having the single-layer antiviral agent-containing layer 10 on the second base material 40 side and the base material 20 are bonded together via an adhesive layer 30. (C3)The surface of the laminate having the single-layer antiviral agent-containing layer 10 on the second base material 40 side and the base material 20 are heated and welded. (C4) Place a laminate having a single layer of the antiviral agent-containing layer 10 on the second substrate 40 into a mold. Pour a resin that has been heated and melted to form a fluid state or dissolved in a solvent to form a fluid state into the mold, and solidify the fluid resin by cooling or solvent drying to mold the resin into the shape of the mold to form the substrate 20, thereby laminating and forming the substrate 20 on the single layer of the antiviral agent-containing layer 10 and on the side of the second substrate 40 of the laminate. (C5) Produce a laminate having a single layer of the antiviral agent-containing layer 10 and an adhesive layer 30, that is, a transfer sheet, on a substrate having releasability. After the surface on the adhesive layer 30 side of the laminate is brought into close contact with the substrate 20, peel off the substrate having releasability.

[0024] That is, specific examples of the layer configuration of the antiviral agent-containing layer in the antiviral adhesive sheet 100 include, for example, the following (1) to (4). Note that the antiviral adhesive sheet 100 may have other layers not exemplified in the following (1) to (4). Examples of other layers include a primer layer for improving adhesion, a pattern ink layer for improving design, and a decorative layer composed of a metal thin film or the like. (1) For example, as shown in FIG. 1, a single layer configuration of the antiviral agent-containing layer 10. (2) For example, as shown in FIG. 2, a configuration having a single layer of the antiviral agent-containing layer 10 on the substrate 20. (3) For example, as shown in FIG. 3(a), a configuration having an adhesive layer and a single layer of the antiviral agent-containing layer 1 on the substrate. (4) For example, as shown in FIG. 3(c), a configuration having an adhesive layer 30, a second substrate 40, and a single layer of the antiviral agent-containing layer 10 on the substrate 20.

[0025] <Layer containing an antiviral agent (also referred to as an antiviral agent-containing layer)> The antiviral agent-containing layer 10 needs to contain an antiviral agent 12. The antiviral agent-containing layer preferably contains an antiviral agent and a binder resin.

[0026] 《Antiviral agent》 Examples of the antiviral agent 12 include, as typical ones, "an antiviral agent obtained by supporting or containing metal ions on a carrier", "particles of an imidazole compound", "particles containing a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound", "a copper-based antiviral agent", "a zinc-based antiviral agent", and "a radioactive compound". Hereinafter, "an antiviral agent obtained by supporting or containing metal ions on a carrier" may be referred to as "antiviral agent 1", "particles of an imidazole compound" may be referred to as "antiviral agent 2", "particles containing a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound" may be referred to as "antiviral agent 3", "a copper-based antiviral agent" may be referred to as "antiviral agent 4", "a zinc-based antiviral agent" may be referred to as "antiviral agent 5", and "a radioactive compound" may be referred to as "antiviral agent 6".

[0027] From the viewpoint of enhancing antiviral properties, it is preferable that the antiviral agent is present in at least a part of the region near the surface where the antiviral agent-containing layer is exposed. By increasing the content of the antiviral agent or adjusting the specific gravity of the antiviral agent and the binder resin, it is easier to satisfy the above configuration.

[0028] Note that even if the antiviral agent is buried in the antiviral agent-containing layer, the antiviral properties can be exhibited by the following action. For example, atoms, ions, compound molecules, etc. having antiviral properties such as silver ions are released from the antiviral agent, or the antiviral agent itself migrates (bleeds) from the inside of the antiviral agent-containing layer 10 to the surface, so that substances having antiviral properties are present on the surface and in the vicinity of the surface of the antiviral agent-containing layer, whereby the antiviral properties can be exhibited. Further, when the antiviral agent is a radioactive compound, antiviral properties can be exhibited by radiation of virus-killing radiation such as α-rays and β-rays on the surface of the antiviral agent-containing layer. Alternatively, the virus may penetrate (or enter) from the surface of the antiviral agent-containing layer 10 into the interior near the surface through fine voids such as the gaps at the interface between the antiviral agent 12 and the binder resin 11, cracks in the antiviral agent-containing layer 10 itself, and porous structures, and come into contact with the antiviral agent 12 inside the antiviral agent-containing layer 10. In such a case, the antiviral agent 12 inside the antiviral agent-containing layer 10 can exhibit sufficient antiviral properties.

[0029] - Antiviral agent 1 - The antiviral agent 1 is an antiviral agent in which metal ions are supported or contained in a carrier. The metal ions of the antiviral agent 1 are preferably either silver or zinc, and more preferably contain both silver and zinc for discoloration suppression and cost reduction. Silver is superior in antiviral properties to zinc, but has a high cost and is prone to discoloration due to oxidation. Zinc can suppress the discoloration caused by the oxidation of silver. Therefore, by containing both silver and zinc, discoloration can be suppressed and the cost can be reduced.

[0030] As the carrier of the antiviral agent 1, inorganic compounds such as zeolite, apatite, glass, molybdenum, zirconium phosphate, and titanium phosphate are preferable, and among them, porous inorganic compounds are preferable.

[0031] Zeolite is an aluminosilicate of an alkali metal or an alkaline earth metal, and both natural zeolite and synthetic zeolite can be used. Also, zeolite is classified into A-type, faujasite-type (X-type, Y-type), mordenite-type, clinoptilolite-type, etc. according to the crystal structure, and any of them can be used.

[0032] Apatite is a general term for minerals having a composition represented by the following general formula. M 10 (ZO4)3X2 In the above formula, M represents Ca, Ba, Mg, Na, K, Fe, Al, etc., Z represents P, S, Si, As, etc., and X represents F, Cl, O, OH, etc. Representative examples corresponding to the above formula include fluorapatite "Ca 10 (PO4)6F2" and hydroxyapatite "Ca 10 (PO4)6(OH)2".

[0033] Examples of glass include soda lime glass, borosilicate glass, lead glass, aluminosilicate glass, boric acid glass, and phosphoric acid glass.

[0034] As a method for supporting or containing metal ions on the carrier, a known method may be appropriately selected in consideration of the form and processing conditions of the antiviral agent-containing layer, the required level of antiviral properties, etc. Here, "containing metal ions" means holding metal ions or a substance capable of generating metal ions in the carrier in some form. Also, "substance capable of generating metal ions" means a substance that generates metal ions due to external factors or time-dependent factors, such as a substance that generates metal ions by dissolving in water or the like. Specific forms of loading or containing include methods of loading by physical adsorption or chemical adsorption; methods of loading by ion exchange reaction; methods of loading by a binder; methods of containing by implanting a silver compound into the carrier; methods of loading or containing by forming a thin layer of a silver compound on the surface of the carrier by thin film formation methods such as vapor deposition, solution deposition reaction, sputtering, etc.; methods of melting and kneading simple substances such as glass and metals at high temperature; etc.

[0035] The antiviral agent 1 is preferably in particulate form. Examples of the shape of the particles of the antiviral agent 1 include spheres, ellipsoids, polyhedrons, scale shapes, etc., and there are no particular restrictions.

[0036] The average particle diameter of the antiviral agent 1 is preferably 0.1 to 10.0 μm, more preferably 0.5 to 5.0 μm, and even more preferably 1.0 to 4.0 μm. By setting the average particle diameter to 0.1 μm or more, the stability of the ink containing the antiviral agent 1 can be easily obtained. Further, by setting the average particle diameter to 10.0 μm or less, it is easy to suppress appearance defects, deterioration of scratch resistance and stain resistance, and whitening of the coating film. Furthermore, it is easy to suppress wear of members of the coating apparatus (coating roll, doctor blade, etc.).

[0037] When the average particle diameter of the antiviral agent 1 is defined as D1 and the thickness of the antiviral agent-containing layer is defined as T, D1 / T is preferably 1.0 or less, more preferably 0.7 or less, and even more preferably 0.5 or less. By setting D1 / T to 1.0 or less, it is easy to suppress deterioration of stain resistance and whitening of the coating film. Furthermore, it is easy to suppress wear of members of the coating apparatus (coating roll, doctor blade, etc.).

[0038] In this specification, the average particle diameter means the mass average value d50 measured in the particle size distribution measurement by the laser light diffraction method.

[0039] The amount of metal ions in the antiviral agent 1 is preferably 0.1 to 30.0 parts by mass, more preferably 0.5 to 25.0 parts by mass, and even more preferably 1.0 to 20.0 parts by mass with respect to 100 parts by mass of the carrier. Here, the "amount of metal ions" means both the supported metal ions and the contained metal ions. By setting the amount of metal ions to 0.1 part by mass or more, the antiviral property can be easily improved. Further, by setting the amount of metal ions to 30.0 parts by mass or less, discoloration due to light can be easily suppressed.

[0040] The content of the antiviral agent 1 is preferably 0.1 to 50.0 parts by mass, more preferably 0.5 to 17.0 parts by mass, and even more preferably 1.0 to 15.0 parts by mass with respect to 100 parts by mass of the binder resin. By setting the content of the antiviral agent 1 to 0.1 part by mass or more, the antiviral property can be easily improved. By setting the content of antiviral agent 1 to 50.0 parts by mass or less, discoloration due to light can be easily suppressed. Also, by setting the content of antiviral agent 1 to 50.0 parts by mass or less, a decrease in the physical properties of the coating film such as coating film strength and scratch resistance can be suppressed. Furthermore, by setting the content of antiviral agent 1 to 50.0 parts by mass or less, a decrease in stain resistance and whitening of the coating film can be easily suppressed, and furthermore, abrasion of the members of the coating device (coating roll, doctor blade, etc.) can be easily suppressed. In addition, when the binder resin is a cured product of the curable resin composition, the content of antiviral agent 1 is preferably set to be relatively high within the above range.

[0041] - Antiviral agent 2 - Antiviral agent 2 is particles of an imidazole compound. Normally, an imidazole-based compound is dissolved in an ink containing the imidazole-based compound. The reason for this is to uniformly diffuse the imidazole-based compound within an arbitrary layer and to exert the effect of the imidazole-based compound throughout the layer. Therefore, in the usual method of using an imidazole-based compound, the imidazole-based compound does not exist in the form of particles within the antiviral agent-containing layer. That is, in this embodiment, it is characterized in that the imidazole-based compound maintains a particulate state.

[0042] An imidazole-based compound is a compound containing an imidazole skeleton as a structural unit of the molecule. In this embodiment, among various imidazole-based compounds, those that maintain a particulate form within the antiviral agent-containing layer can be used. Such imidazole-based compounds are preferably those that are difficult to dissolve in water and organic solvents. Examples include methyl-benzimidazol-2-ylcarbamate (alias: carbendazim) and polymerized imidazole-based compounds. In addition, methyl - benzimidazol - 2 - yl carbamate (alias: carbendazim), even if it is a polymerized imidazole - based compound, may dissolve depending on the solvent, so caution is required. For example, for methyl - benzimidazol - 2 - yl carbamate (alias: carbendazim), it is preferable to use methyl ethyl ketone, ethyl acetate, etc. as the solvent.

[0043] The shape of the antiviral agent 2 is not particularly limited, and examples include spheres, ellipsoids, polyhedrons, scale - like shapes, etc.

[0044] The average particle diameter of the antiviral agent 2 is preferably 0.1 - 10.0 μm, more preferably 0.2 - 8.0 μm, and even more preferably 0.3 - 7.0 μm. By setting the average particle diameter to 0.1 μm or more, the stability of the ink containing the antiviral agent 2 is likely to be obtained. Also, by setting the average particle diameter to 10.0 μm or less, it is easy to suppress appearance defects, reduction in scratch resistance and stain resistance, and whitening of the coating film.

[0045] When defining the average particle diameter of the antiviral agent 2 as D2 and the thickness of the antiviral agent - containing layer as T, it is preferable that D2 / T is 1.0 or less, more preferably 0.7 or less, and even more preferably 0.5 or less. By setting D2 / T to 1.0 or less, it is easy to suppress appearance defects, reduction in scratch resistance and stain resistance, and whitening of the coating film. The lower limit of D2 / T is not particularly limited, but it is usually 0.01 or more, preferably 0.05 or more.

[0046] The content of the antiviral agent 2 is preferably 0.5 - 20.0 parts by mass, more preferably 1.0 - 13.0 parts by mass, and even more preferably 3.0 - 10.0 parts by mass with respect to 100 parts by mass of the binder resin. By setting the content of the antiviral agent 2 to 0.5 parts by mass or more, the antiviral property can be easily improved. By setting the content of the antiviral agent 2 to 20.0 parts by mass or less, it is possible to suppress a decrease in the physical properties of the coating film such as the coating film strength and scratch resistance. Furthermore, by setting the content of the antiviral agent 2 to 20.0 parts by mass or less, it is easier to suppress a decrease in stain resistance and whitening of the coating film.

[0047] - Antiviral agent 3 - The antiviral agent 3 is particles containing a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound.

[0048] In this specification, the "particles containing a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound" may be "particles containing a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound", or may be "mixed particles of particles containing a styrene polymer derivative compound and particles containing an unsaturated carboxylic acid derivative compound", or a combination thereof.

[0049] The antiviral agent 3 contains a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound. The constituent components of the styrene polymer derivative compound and the unsaturated carboxylic acid derivative compound preferably have at least one structure selected from the group consisting of styrene, sodium sulfonate, acrylic acid, maleic acid, and fumaric acid, and more preferably have both at least one structure of styrene and sodium sulfonate and at least one structure selected from the group consisting of acrylic acid, maleic acid, and fumaric acid.

[0050] The content ratio of the styrene polymer derivative compound and the unsaturated carboxylic acid derivative compound in the antiviral agent 3 is not limited, but the mass ratio is preferably 30:70 to 70:30, and more preferably 40:60 to 60:40. When the antiviral agent 3 is mixed particles of particles (particle A) containing a styrene polymer derivative compound and particles (particle B) containing an unsaturated carboxylic acid derivative compound, the mass ratio of particle A to particle B is preferably 30:70 to 70:30, and more preferably 40:60 to 60:40.

[0051] The reason why antiviral agent 3 exhibits antiviral activity is not necessarily restricted to the mechanism speculated below, but is considered as follows. Influenza virus binds to the sugar chain receptor on the surface of host cells (the sugar chain terminal is sialic acid) and invades into the host cells. Since the copolymer containing styrene sulfonate has an ionic group similar to sialic acid, it is considered to bind to the virus instead of the host cells and capture the virus, thereby preventing the virus from binding to the receptor of the host cells and exerting an antiviral effect. In addition, it is considered that the unsaturated carboxylic acid derivative compound generates a hydroxyl group (OH-) upon contact with moisture, and the hydroxyl group exerts an antiviral action.

[0052] The shape of antiviral agent 3 is not particularly limited, and examples include spheres, ellipsoids, polyhedrons, scale shapes, etc.

[0053] The average particle size of antiviral agent 3 is preferably 0.1 to 10.0 μm, more preferably 0.2 to 8.0 μm, and even more preferably 0.5 to 7.0 μm. By setting the average particle size to 0.1 μm or more, the stability of the ink containing antiviral agent 3 can be easily obtained. Also, by setting the average particle size to 10.0 μm or less, it is easy to suppress appearance defects, reduction in scratch resistance and stain resistance, and whitening of the coating film.

[0054] When the average particle size of antiviral agent 3 is defined as D3 and the thickness of the antiviral agent-containing layer is defined as T, it is preferable that D3 / T is 1.0 or less, more preferably 0.7 or less, and even more preferably 0.5 or less. By setting D3 / T to 1.0 or less, it is easy to suppress appearance defects, reduction in scratch resistance and stain resistance, and whitening of the coating film. The lower limit of D3 / T is not particularly limited, but is usually 0.01 or more, preferably 0.05 or more.

[0055] The content of the antiviral agent 3 is preferably 0.5 to 20.0 parts by mass, more preferably 0.5 to 19.0 parts by mass, still more preferably 1.0 to 17.0 parts by mass, and even more preferably 1.5 to 15.0 parts by mass with respect to 100 parts by mass of the binder resin. By setting the content of the antiviral agent 3 to 0.5 part by mass or more, it is easy to improve the antiviral property. By setting the content of the antiviral agent 3 to 20.0 parts by mass or less, it is possible to suppress a decrease in the physical properties of the coating film such as the coating film strength and scratch resistance. Further, by setting the content of the antiviral agent 3 to 20.0 parts by mass or less, it is easy to suppress a decrease in the stain resistance and whitening of the coating film.

[0056] - Antiviral agents 4 and 5 - The antiviral agent 4 is a copper-based antiviral agent, and the antiviral agent 5 is a zinc-based antiviral agent. Examples of the copper-based antiviral agent include copper oxide particles described in Japanese Patent No. 6145758 and copper iodide particles described in WO2010 / 026730. Examples of the zinc-based antiviral agent include zinc-based inorganic additives described in Japanese Patent No. 6229429.

[0057] - Antiviral agent 6 - The antiviral agent 6 is a radioactive compound.

[0058] As the radioactive compound, in order to prevent adverse effects on health due to radiation, a radioactive compound that emits either or both of α-rays and β-rays with relatively small flight distances in air or vacuum and permeability in various substances is preferred. Further, the radioactive compound preferably emits α-rays or / and β-rays with sufficient energy (quanta) to kill the virus and has a small radiation dose of radiation with large substance permeability such as γ-rays.

[0059] Examples of the radioactive compound that emits α-rays include 241 Am, 243 Am, 226 Ra, 232Examples include Th. As the radioactive compound that emits β-rays, 147 Pm, 210 Po, 90 Sr, 90 Y, etc. may be mentioned.

[0060] 《Binder Resin》 As the binder resin 11, a thermoplastic resin and a cured product of a curable resin composition can be mentioned. The thermoplastic resin and the cured product of the curable resin composition may be mixed.

[0061] Examples of the thermoplastic resin include olefin resins such as polyethylene, polypropylene, polymethylpentene, ionomer, and various olefin-based thermoplastic elastomers; vinyl chloride-based resins such as polyvinyl chloride, polyvinylidene chloride, and vinyl chloride-vinyl acetate copolymer; polyester resins such as polyethylene terephthalate, polybutylene terephthalate, polyethylene naphthalate, ethylene glycol-terephthalic acid-isophthalic acid copolymer, and polyester-based thermoplastic elastomers; acrylic resins such as poly(methyl)acrylate, poly(ethyl)acrylate, poly(butyl)acrylate, and (methyl)acrylate methyl-(methyl)acrylate butyl copolymer; polyamide resins typified by nylon 6 or nylon 66; cellulose-based resins such as triacetate cellulose, cellophane, and celluloid; styrene-based resins such as polystyrene, acrylonitrile-styrene copolymer, and acrylonitrile-butadiene-styrene copolymer (ABS); polyvinyl alcohol; ethylene-vinyl acetate copolymer; ethylene-vinyl alcohol copolymer; polycarbonate resin; urethane resin; polyarylate resin; polyimide resin; etc. Among these, acrylic resins are preferred.

[0062] Examples of the cured product of the curable resin composition include a cured product of a thermosetting resin composition or a cured product of an ionizing radiation curable resin composition. Among them, the cured product of the ionizing radiation curable resin composition is preferred from the viewpoints of scratch resistance and production efficiency.

[0063] The thermosetting resin composition is a composition containing at least a thermosetting resin, and is a resin composition that cures upon heating. Examples of the thermosetting resin include acrylic resin, urethane resin, phenol resin, urea melamine resin, epoxy resin, unsaturated polyester resin, silicone resin, etc. In addition to these thermosetting resins, a curing agent, a curing catalyst, etc. are added to the thermosetting resin composition as necessary.

[0064] Typical examples of the radiation-curable resin composition include an electron beam-curable resin composition and an ultraviolet ray-curable resin composition. Among these, from the viewpoints of having less odor because a polymerization initiator is not required and being less likely to be colored, the electron beam-curable resin composition is preferable. Further, when the antiviral agent-containing layer contains the ultraviolet absorber described later, the electron beam-curable resin composition is also preferable in that it is easier to increase the crosslinking density of the antiviral agent-containing layer and easier to improve the scratch resistance and stain resistance.

[0065] The radiation-curable resin composition is a composition containing a compound having a radiation-curable functional group (hereinafter also referred to as "radiation-curable compound"). The radiation-curable functional group is a group that crosslinks and cures upon irradiation with radiation, and preferably includes functional groups having an ethylenic double bond such as (meth)acryloyl group, vinyl group, allyl group, etc. In addition, epoxy group and oxetanyl group are also included as the radiation-curable functional group. In this specification, the (meth)acryloyl group means an acryloyl group or a methacryloyl group. Also, in this specification, (meth)acrylate means acrylate or methacrylate. In addition, radiation means those having energy quanta capable of polymerizing or crosslinking molecules among electromagnetic waves or charged particle beams, and usually ultraviolet rays (UV) or electron beams (EB) are used, but other electromagnetic waves such as X-rays and γ-rays, and charged particle beams such as α-rays and ion beams are also included. The radiation-curable compound can be appropriately selected and used from among polymerizable monomers and polymerizable oligomers (sometimes referred to as "polymerizable prepolymers") that have been conventionally used as radiation-curable resins.

[0066] The radiation-curable compound is more preferably a compound having two or more ethylenically unsaturated bond groups, and among them, a polyfunctional (meth)acrylate-based compound having two or more ethylenically unsaturated bond groups is even more preferable. As the polyfunctional (meth)acrylate-based compound, either a monomer or an oligomer can be used.

[0067] Among the polyfunctional (meth)acrylate-based compounds, examples of the bifunctional (meth)acrylate-based monomer include ethylene glycol di(meth)acrylate, bisphenol A tetraethoxydiacrylate, bisphenol A tetrapropoxydiacrylate, 1,6-hexanediol diacrylate, and the like. Examples of the (meth)acrylate-based monomer having three or more functional groups include trimethylolpropane tri(meth)acrylate, pentaerythritol tri(meth)acrylate, pentaerythritol tetra(meth)acrylate, dipentaerythritol hexa(meth)acrylate, dipentaerythritol tetra(meth)acrylate, isocyanuric acid-modified tri(meth)acrylate, and the like. Examples of the polyfunctional (meth)acrylate-based oligomer include acrylate-based polymers such as urethane (meth)acrylate, epoxy (meth)acrylate, polyester (meth)acrylate, and polyether (meth)acrylate.

[0068] Urethane (meth)acrylate can be obtained, for example, by the reaction of a polyhydric alcohol and an organic diisocyanate with hydroxy (meth)acrylate.

[0069] Preferred epoxy (meth) acrylates include (meth) acrylates obtained by reacting a trifunctional or higher aromatic epoxy resin, alicyclic epoxy resin, aliphatic epoxy resin, etc. with (meth) acrylic acid, (meth) acrylates obtained by reacting a bifunctional or higher aromatic epoxy resin, alicyclic epoxy resin, aliphatic epoxy resin, etc. with a polybasic acid and (meth) acrylic acid, and (meth) acrylates obtained by reacting a bifunctional or higher aromatic epoxy resin, alicyclic epoxy resin, aliphatic epoxy resin, etc. with phenols and (meth) acrylic acid.

[0070] The above ionizing radiation curable resin can be used alone or in combination of two or more.

[0071] When the ionizing radiation curable compound is an ultraviolet curable compound, the ionizing radiation curable resin composition preferably contains additives such as a photopolymerization initiator and a photopolymerization accelerator. Examples of the photopolymerization initiator include one or more selected from acetophenone, benzophenone, α-hydroxyalkylphenone, Michler's ketone, benzoin, benzyldimethyl ketal, benzoyl benzoate, α-acyl oxime ester, thioxanthones, etc. In addition, the photopolymerization accelerator can reduce the polymerization inhibition by air during curing and increase the curing rate. Examples thereof include one or more selected from isoamyl p-dimethylaminobenzoate, ethyl p-dimethylaminobenzoate, etc.

[0072] 《Additives》 The antiviral agent-containing layer may contain additives such as an antioxidant, a light stabilizer, an ultraviolet absorber, a matting agent, and a coloring agent.

[0073] 《Thickness》 From the viewpoint of the balance between processing characteristics and scratch resistance, the thickness of the single-layer portion of the antiviral agent-containing layer 10 can be, for example, 1.0 μm or more and 10,000 μm (1 cm) or less. When the antiviral adhesive sheet 100 is composed of a single layer of the antiviral agent-containing layer, it is preferable to make the thickness of the antiviral agent-containing layer relatively thick. In the case of a single layer, the thickness of the antiviral agent-containing layer is preferably 1.0 μm or more and 10,000 μm or less, more preferably 10 μm or more and 5,000 μm or less. On the other hand, in the case where the antiviral agent-containing layer has a form with a base material, the self-supportability and durability against external forces are borne by the base material, the antiviral effect saturates if the thickness is a certain degree or more, and considering that the processability decreases as the thickness of the single-layer part of the antiviral agent-containing layer increases, etc., the thickness of the single-layer part of the antiviral agent-containing layer is preferably made into a thin film. In the case of a form with a base material, from the viewpoint of the balance between processability and scratch resistance, the thickness of the single-layer antiviral agent-containing layer is preferably 1.5 μm or more and 30 μm or less, more preferably 2 μm or more and 20 μm or less, still more preferably 3 μm or more and 15 μm or less.

[0074] From the viewpoint of handleability, the antiviral agent-containing layer preferably has a configuration having a single layer of the antiviral agent-containing layer on the base material. Further, the antiviral agent-containing layer having a single layer of the antiviral agent-containing layer on the base material may further have other layers such as an adhesive layer and a decorative layer.

[0075] <Suction cup adhesive layer> The suction cup adhesive layer 50 is laminated on the surface on one side of the antiviral agent-containing layers 10, 10', and 10'', and on the surface on the opposite side of the side that is exposed on the outermost surface after the antiviral adhesive sheet 100 is adhered to the surface of the adherend. That is, the antiviral adhesive sheet 100 is adhered to the surface of the adherend through the suction cup adhesive layer 50. Unlike ordinary adhesives, the suction cup adhesive layer 50 exhibits instantaneous adhesive force simply by contact and pressure application. Therefore, processes such as time elapse, drying, and energy supply such as heating or ionizing radiation irradiation are not required for the manifestation of adhesive force. As a result, the antiviral adhesive sheet 100 can be easily adhered to the surface of the adherend, and antiviral properties can be imparted to its surface. Further, by setting the adhesive force of the suction cup adhesive layer 50 to be weak, when adhesion defects such as misalignment, wrinkles, and slack occur during adhesion, after the antiviral adhesive sheet 100 is once peeled off, the problem is solved, and then the peeled antiviral adhesive sheet 100 can be re-adhered (re-stuck).

[0076] The suction cup adhesive layer 50 is provided with a plurality of concave shapes 50a that are open on both sides thereof. Further, the suction cup adhesive layer 50 has elasticity, and since the plurality of concave shapes 50a each act as a fine suction cup, it can exhibit adhesive force (suction force) with respect to various adherends.

[0077] The suction cup adhesive layer 50 is formed, for example, using a liquid resin composition (acrylic emulsion) disclosed in Japanese Patent Application Laid-Open No. 2017-36404 (hereinafter Patent Document 3). In particular, it is preferably made of a one-component curable acrylic resin. If it is a one-component curable type, problems such as hardening progressing in a heated environment like a two-component curable type and the adhesive force becoming high and difficult to peel off, and glue residue occurring when peeled off, are less likely to occur. Also, if it is an acrylic resin, since it does not contain chlorine atoms, basically only carbon dioxide and water are emitted even when incinerated at the time of disposal, which is advantageous in terms of the environment.

[0078] The thickness t of the suction cup adhesive layer 50 is desirably 1 μm or more and 500 μm or less. If it is less than the lower limit value of the above layer thickness range, it becomes difficult to form the concave shape, or the size of the concave shape becomes too small, resulting in a decrease in adhesion (suction) characteristics. Also, if it exceeds the upper limit value of the above layer thickness range, the flexibility of the anti-slip floor decorative sheet decreases, and workability deteriorates. Furthermore, in order to uniformly provide the concave shapes 50a on both sides of the suction cup adhesive layer 50, it is desirable that the thickness t of the suction cup adhesive layer 50 be in the range of 20 μm ≤ t ≤ 40 μm. This will be described later.

[0079] The size and density of the concave shapes 50a of the suction cup adhesive layer 50 can be adjusted by changing various conditions in the manufacturing process described later. For example, as an index indicating the degree to which the concave shapes 50a are included, the density of the suction cup adhesive layer 50 can be used. The density of the suction cup adhesive layer 50 is not particularly limited, but for example, it can be 0.1 g / cm 3 or more and 0.6 g / cm 3 or less. Also, the size of the concave shapes 50a is not particularly limited, but for example, it can be 1 μm or more and 300 μm or less.

[0080] When attaching the antiviral adhesive sheet 100 to an adherend, by bringing the suction cup adhesive layer 50 into contact with the adherend and applying an appropriate pressure, the concave shapes 50a existing in large numbers on the exposed surface of the adhesive layer are elastically deformed, and thus the adherend is adsorbed (adhered) to the adherend by the same action as a conventional micro suction cup.

[0081] That is, due to the elastic deformation around the concave shapes 50a, a force that tries to return the concave shapes 50a from the deformed state to the original shape acts on the concave shapes 50a. Due to this force, the sealed space inside the concave shapes 50a becomes a negative pressure, and an adsorption action to the adherend occurs. Note that the adsorption force of a single concave shape 50a is weak, but since a large number of concave shapes 50a are formed, the necessary adsorption force can be ensured as a whole. Also, when manufacturing the suction cup adhesive layer 50, if the amount of the concave shapes 50a included is adjusted using, for example, the density as a parameter, the adhesive force (adsorption force) of the suction cup adhesive layer 50 can be adjusted.

[0082] (Verification experiment on the concave shapes 50a of the suction cup adhesive layer 50) As described above, in the present invention, the concave shape 50a of the suction cup adhesive layer 50 has a great influence on the adhesive force. If the concave shape 50a is not provided evenly on both sides of the suction cup adhesive layer 50, the adhesive force (suction force) of one surface of the adhesive layer may decrease or increase compared to the other surface. Further, by providing the concave shape 50a evenly on both sides of the suction cup adhesive layer 50, the physical properties of the suction cup adhesive layer 50 also become homogeneous, which is preferable for the manifestation of sufficient adhesive force on both sides of the suction cup adhesive layer 50 and re - peelability from the adherend.

[0083] In order to provide the concave shape 50a evenly on both sides of the suction cup adhesive layer 50, it is important to control the coating amount (thickness t) of the suction cup adhesive layer 50. In this regard, Patent Document 3 does not consider this at all and simply states that as long as micro - suction cups are formed. In FIG. 2 of Patent Document 3, which is a cross - sectional photograph of Example 1 formed with a WET film thickness of 800 μm, although a fine suction cup structure is formed in the portion shown as the surface having micro - suction cups, in the portion shown as the surface peeled from the glass substrate, a structure that seems to be extremely large bubbles incomparable to the previous fine suction cup structure can be confirmed. That is, in the configuration of Patent Document 3 although micro - suction cups (corresponding to the concave shape 50a in the present embodiment) are formed on one surface of the adhesive layer, on the other surface, micro - suction cups (concave shape 50a) are hardly formed.

[0084] The applicant of this application also conducted a verification experiment on this point. As a verification experiment, four types of adhesive layer samples were prepared, and the concave shape 50a on both sides was observed by SEM. The samples are the following four types. Sample 1: Thickness t of the adhesive layer = 25 μm Sample 2: Thickness t of the adhesive layer = 30 μm Sample 3: Thickness t of the adhesive layer = 35 μm Sample 4: Thickness t of the adhesive layer ≒ 2000 μm Note that the thickness t of the adhesive layer in the above sample is the thickness t after drying. For Samples 1 to 3, the bubble-containing composition after foaming treatment was applied to the glass surface using a coater, and drying treatment was performed using a drying oven at 100°C. For Sample 4, it was applied by dropping onto the glass surface and naturally dried at room temperature. The reason for changing the drying conditions for Sample 4 is to verify the description in Patent Document 3 that room temperature drying is sufficient. Also, for all samples, the density of the adhesive layer after foaming treatment was 0.4 g / cm 3 was used.

[0085] Regarding Samples 1 to 3 in which the thickness t of the adhesive layer was controlled, it was confirmed that the fine concave shape 50a was evenly formed on both sides. On the other hand, in Sample 4 with a thick film thickness, an extreme difference in the size of the concave shape 50a was observed between the dried surface and the glass side surface, and the same result as in FIG. 2 of Patent Document 3 was obtained. Therefore, in order to evenly provide the concave shape 50a on both sides of the suction cup adhesive layer 50, it can be determined that it is desirable that the thickness t of the suction cup adhesive layer 50 be in the range of 20 μm ≤ t ≤ 40 μm.

[0086] Also, the coating amount of the suction cup adhesive layer 50 is preferably 13 g / m 2 or more and 70 g / m 2 or less. When it exceeds 70 g / m 2 , there is a problem that it takes a long time to dry. If heating is performed to shorten it, adverse effects such as shrinkage due to heat of a base material having releasability (a layer different from the base material having releasability depending on the layer structure and the coating object of the suction cup adhesive layer) are likely to occur. On the other hand, when it is less than 13 g / m 2 , there is a problem that a portion where the coating liquid is repelled (the coating liquid is not applied) occurs in the coating process, that is, it becomes difficult to uniformly apply the coating liquid.

[0087] Here, regarding the state where the concave shape 50a is evenly provided on both sides of the suction cup adhesive layer 50, more specifically, it is desirable to satisfy the following relationship. The average value of the diameters of the openings of the concave shape 50a that open to the surface on the antiviral agent-containing layer side is D ave 1, and the average value of the diameters of the openings of the concave shape 50a that open to the surface on the substrate side having releasability is D ave When 2, |D ave 1 - D ave 2| / D ave 2 ≤ 0.5 It is desirable to satisfy the relationship. Also, |D ave 1 - D ave 2| / D ave 2 ≤ 0.25 It is more desirable to satisfy the relationship.

[0088] By satisfying these relationships, the difference in adhesive force on both sides of the suction cup adhesive layer can be reduced, and sufficient adhesive force on both sides of the suction cup adhesive layer 50 and re-peelability from the adherend can be favorably exhibited. Note that since it is practically impossible to obtain the average of all the diameters of the openings, here, within an observation range of 1500 μm × 1100 μm, the diameters of three openings were measured in order from the opening with the largest diameter, and the average value was used.

[0089] Here, for Samples 1 to 4, the openings were measured, and |D ave 1 - D ave 2| / D ave When 2 was obtained, it was 0.04 for Sample 1, 0.06 for Sample 2, 0.12 for Sample 3, and 0.69 for Sample 4.

[0090] <Substrate> Examples of the form of the substrate include flat plates such as films, sheets, and plates, and there is no particular limitation. Note that films, sheets, and plates are often referred to as films, sheets, and plates in order from those with relatively small thicknesses, but in this specification, unless otherwise specified, these three are not distinguished.

[0091] Examples of the constituent materials of the base material include resins, metals, non-metallic inorganic materials, fibrous materials, and wood-based materials, etc., and they can be appropriately selected according to the application.

[0092] The base material may be a single layer, or may be a laminate formed by laminating two or more layers made of the above materials. When the base material is a laminate of two or more layers, it is preferable that two or more layers of different materials are laminated to complement the various properties of the materials of each layer. Examples of the base material formed by laminating two or more layers include the following A to J. Note that " / " indicates the interface of each layer. (A) Resin / Wood-based material (B) Resin / Metal (C) Resin / Fibrous material (D) Resin / Non-metallic inorganic material (E) Resin 1 / Resin 2 (F) Metal / Wood-based material (G) Metal / Non-metallic inorganic material (H) Metal / Fibrous material (I) Metal 1 / Metal 2 (J) Non-metallic inorganic material / Fibrous material

[0093] In the above E, Resin 1 and Resin 2 indicate different types of resins from each other (for example, Resin 1 is an olefin resin and Resin 2 is an acrylic resin). Also, in the above H, Metal 1 and Metal 2 indicate different types of metals from each other (for example, Metal 1 is copper and Metal 2 is chromium).

[0094] Also, when the base material is a laminate such as the above A to J, it may have a layer (such as an adhesive layer) for strengthening the adhesive force between the constituent layers of the laminate.

[0095] Examples of the resin used as the base material include those made of various synthetic resins or natural resins. As the synthetic resin, thermoplastic resins and curable resins can be used.

[0096] Examples of the thermoplastic resin include the thermoplastic resins exemplified as the binder resin of the anti-virus agent-containing layer. Examples of the curable resin include the thermosetting resin and the radiation curable resin exemplified as the binder resin of the antiviral agent-containing layer. Examples of the natural resin include natural rubber, rosin, and amber.

[0097] Examples of the metal used as the base material include alloys containing aluminum such as aluminum or duralumin, iron or carbon steel, alloys containing iron such as stainless steel, alloys containing copper such as copper or brass, bronze, gold, silver, chromium, nickel, cobalt, tin, titanium, and the like. Further, as the metal base material, those obtained by plating these metals or the like can also be used.

[0098] Examples of the non-metallic inorganic material used as the base material include non-ceramic-based ceramic materials such as cement, ALC (lightweight cellular concrete), gypsum, calcium silicate, and wood chip cement, ceramic-based ceramic materials such as ceramics, earthenware, glass, and hollow, and natural stones such as limestone (including marble), granite, and andesite.

[0099] Examples of the fibrous material used as the base material include papers such as tissue paper, kraft paper, fine paper, Japanese paper, titanium paper, linter paper, sulfuric acid paper, paraffin paper, parchment paper, glassine paper, backing paper for wallpaper, cardboard, and base paper for gypsum board, protein-based or cellulose-based natural fibers such as polyester resin fibers, acrylic resin fibers, silk, cotton, and hemp, and woven or non-woven fabrics made of fibers such as glass fibers and carbon fibers. These papers may be added with resins such as acrylic resin, styrene-butadiene rubber, melamine resin, and urethane resin (resin impregnation after papermaking or internal filling during papermaking) in order to increase the inter-fiber strength of the paper base material or the strength between the paper and other layers and to prevent fluffing. Examples of the paper added with resin include paper with enhanced inter-paper strength and resin-impregnated paper. Further, as an example of the base material when a resin layer is laminated on the fibrous material layer, there can be mentioned wallpaper base fabrics such as those obtained by laminating a resin layer such as a vinyl chloride resin layer, an olefin resin layer, or an acrylic resin layer on the surface of the backing paper for wallpaper, which is often used in the building materials field.

[0100] Examples of the wood-based materials used as the base material include cedar, cypress, pine, oak, lauan, teak, rubber tree, etc. Examples of the form of the base material of the wood-based material include veneer, plywood, laminated wood, particle board, veneer board, etc.

[0101] The shape and dimensions of the base material are not particularly limited, and may be appropriately selected according to the use, desired various properties, and processability. When the base material is in the flat plate shape of a film, sheet, or plate, there is a thickness as a typical dimension in the design of the article. Such a thickness is not particularly limited either, but generally, from the viewpoints of manufacturing processability, mechanical strength, usability, and economy, it is about 10 μm or more and 10 cm or less. In the case of a film or sheet form, usually, those with a thickness of about 20 μm or more and 500 μm or less are selected, and in the case of a plate form, usually, those with a thickness of about 1 mm or more and 2 cm or less are selected.

[0102] In order to improve the adhesion between the base material and other layers constituting the single layer of the antiviral agent-containing layer 10, or the adhesion between the base material and the member laminated with the antiviral adhesive sheet 100, physical surface treatments such as oxidation method and roughening method, or surface treatments such as chemical surface treatment can be performed on one or both sides of the base material. Examples of the oxidation method include corona discharge treatment, chromium oxidation treatment, flame treatment, hot air treatment, ozone-ultraviolet treatment method, etc., and examples of the roughening method include sandblasting method, solvent treatment method, etc. These surface treatments are appropriately selected according to the type of the base material, but generally, the corona discharge treatment method is preferably used in terms of the effect of the surface treatment and operability, etc.

[0103] <Adhesive layer> Examples of the adhesive constituting the adhesive layer 30 for laminating the single layer of the antiviral agent-containing layer 10 on the base material 20 include general-purpose adhesives such as moisture-curing adhesives, anaerobic-curing adhesives, dry-curing adhesives, UV-curing adhesives, heat-sensitive adhesives (for example, hot melt adhesives), etc. Examples of the above-mentioned various adhesives include urethane-based adhesives, acrylic-based adhesives, epoxy-based adhesives, rubber-based adhesives, etc. Among these, urethane-based adhesives are preferable in terms of adhesive strength.

[0104] Examples of urethane adhesives include adhesives using a two-component curable urethane resin containing various polyol compounds such as polyether polyol, polyester polyol, and acrylic polyol, and a curing agent such as an isocyanate compound.

[0105] The thickness of the adhesive layer is preferably 0.1 μm or more and 60 μm or less, more preferably 1 μm or more and 50 μm or less, and even more preferably 5 μm or more and 40 μm or less.

[0106] <Second substrate> Examples of the second substrate include the same substrates as those described above. The second substrate is often used as a support when forming a single layer of the antiviral agent-containing layer. For this reason, a resin substrate is preferable for the second substrate in terms of handleability. Also, the thickness of the second substrate is preferably 10 to 300 μm, more preferably 20 to 200 μm, and even more preferably 30 to 150 μm for handleability.

[0107] <Antiviral activity value> The antiviral pressure-sensitive adhesive sheet 100 of this embodiment preferably has an antiviral activity value measured by the following method of 2.0 or more. The following method is a method compliant with ISO21702.

[0108] 《Method for measuring antiviral activity value》 Drop 0.4 ml of virus solution onto a 5 cm square test piece (antiviral processed product and unprocessed product), and cover it with a 4 cm square film. Leave this test piece standing at 25 °C for 24 hours. After standing, wash and collect the virus on the test piece, and measure the virus infectious titer. Calculate the antiviral activity value according to the following formula (1). R = Ut - At (1) R: Antiviral activity value Ut: Average of the common logarithm of the virus infectious titer (PFU / cm 2 ) after standing for 24 hours of the unprocessed product At: Virus infectious titer (PFU / cm) after standing for 24 hours of the antiviral processed product2 The average of the common logarithm of (

[0109] <Haze> In the form where the antiviral adhesive sheet 100 of the present embodiment has transparency, there are cases where high haze like frosted glass is required and cases where low haze is required. When low haze is required, the haze is preferably 30% or less, and more preferably 20% or less. Haze means the haze defined in JIS K7136:2000. In order to reduce the haze, it is preferable to reduce the refractive index difference between the antiviral agent and the binder resin, reduce the content of the antiviral agent, or reduce the thickness of the antiviral agent-containing layer.

[0110] <Use> The antiviral adhesive sheet 100 of the present disclosure is used, for example, in various members, products, daily life spaces, business or business activity sites, medical sites, etc. as described below, with the location where antiviral properties should be imparted as the adherend. It can be preferably used when imparting antiviral properties to the surface of such an adherend relatively easily and in a short time even by a non-skilled person. (1) The surfaces of interior parts such as walls, floors, and ceilings of buildings such as houses, offices, stores, hospitals, and clinics. (2) The surfaces of exterior parts such as outer walls, roofs, eaves ceilings, and door pockets of buildings such as houses, offices, stores, hospitals, and clinics. (3) The surfaces of fittings such as windows, window frames, doors, and door frames (interior or exterior parts); the surfaces of accessories (such as handles) attached to the fittings; the surfaces of jigs for the fittings. (4) The surfaces of handrails, waist walls, skirtings, thresholds, duck eaves, and lintel members. (5) The surfaces of outdoor (exterior) parts such as walls, gates, pillars of drying racks, and handrails. (6) The surface materials of furniture such as wardrobes, desks, chairs, cupboards, and kitchen sinks; the surface materials of accessories (such as handles) attached to the furniture; the surfaces of jigs for the furniture. (7) The surface materials of the casings of various household appliances such as television receivers, radio receivers, refrigerators, microwave ovens, washing machines, fans, and air conditioners; the surface materials of accessories (such as handles, switches, and touch panels) attached to the household appliances; the surfaces of jigs for the household appliances. (8) Surfaces of OA equipment such as various computing devices like electronic copiers, facsimile machines, printers, personal computers, etc.; surfaces of housings of various OA equipment of ATM devices in financial institutions such as banks and post offices; surfaces of accessories (such as keyboards and touch panels) attached to various OA equipment; surfaces of jigs for various OA equipment. (9) Interior or exterior parts (such as walls, floors, ceilings, handrails, pillars, control panels, levers, handles, steering wheels, etc., which are control devices) of vehicles such as automobiles and railway vehicles, and vehicles such as ships and airplanes. (10) Partitions of various buildings; shielding plates or shielding curtains for preventing droplet infection of viruses at windows, accounting settlement places, etc. in stores, offices, government offices, etc.; facial protectors such as protective faces (face guards) and protective glasses (goggles); or their surfaces. (11) Business forms such as vouchers; passbooks; cards such as cash cards, credit cards, and point cards of financial institutions; or their surfaces. (12) Bottles made of glass, resin, etc.; metal cans; resin flexible packaging materials such as resin retort containers; packaging materials such as various tubes; or their surfaces.

[0111] In the above (6), the case of applying the antiviral adhesive sheet 100 of the present disclosure with a desk as the adherend is exemplified. In this case, it is preferable to apply the antiviral adhesive sheet 100 to the working surface (horizontal surface) of the desk. In this case, it is preferable that the antiviral adhesive sheet 100 can be used as a desk mat as it is. In the example where the antiviral adhesive sheet 100 is used as a desk mat, the antiviral agent-containing layer 10 will constitute the surface during the use of the desk mat.

Explanation of Reference Numerals

[0112] 100: Antiviral adhesive sheet 10, 10´, 10´´: Antiviral agent-containing layer 11: Binder resin 12: Antiviral agent 20: Base material 30: Adhesive layer 40: Second base material 50: Suction cup adhesive layer 50a: Concave shape

Claims

1. An antiviral adhesive sheet formed by laminating a sucker adhesive layer on one side surface of an antiviral agent-containing layer, wherein the antiviral agent contained in the antiviral agent-containing layer is formed by carrying or containing metal ions on a carrier, the average particle diameter of the antiviral agent is 0.1 to 10.0 μm, and the amount of metal ions in the antiviral agent is 0.1 to 30.0 parts by mass with respect to 100 parts by mass of the carrier, The suction cup adhesive layer has a plurality of concave shapes on both sides, and the average value of the diameters of the respective openings of the concave shapes opening to one surface is D ave 1 When the average value of the diameters of the respective openings of the concave shapes opening to the other surface of the suction cup adhesive layer is D ave 2 then | D ave 1 - D ave 2 | / D ave 2 ≤0.5 an antiviral adhesive sheet satisfying the relationship.

2. An antiviral adhesive sheet formed by laminating a sucker adhesive layer on one side surface of an antiviral agent-containing layer, wherein the antiviral agent contained in the antiviral agent-containing layer is particles containing a styrene polymer derivative compound and an unsaturated carboxylic acid derivative compound, the average particle diameter of the antiviral agent is 0.1 to 10.0 μm, and the content of the antiviral agent is 0.5 to 20.0 parts by mass with respect to 100 parts by mass of the binder resin, The suction cup adhesive layer has a plurality of concave shapes on both sides, and the average value of the diameters of the respective openings of the concave shapes that open to one surface is D ave 1 is defined as such, and when the average value of the diameters of the respective openings of the concave shapes that open to the other surface of the suction cup adhesive layer is D ave 2 then |D ave 1 -D ave 2 | / D ave 2 ≤0.5 an antiviral adhesive sheet satisfying the relationship.

3. The antiviral adhesive sheet according to claim 1 or claim 2, wherein the sucker adhesive layer is made of a one-component curable acrylic resin.

4. The coating amount of the suction cup adhesive layer is 13 g / m 2 or more and 70 g / m 2 or less. The antiviral adhesive sheet according to any one of claims 1 to 3.

Images